3 years ago

A phase 1 trial of SGN‐CD70A in patients with CD70‐positive, metastatic renal cell carcinoma

Sumanta K. Pal, Andres Forero-Torres, John A. Thompson, John C. Morris, Saurabh Chhabra, Christopher J. Hoimes, Nicholas J. Vogelzang, Thomas Boyd, Paulo G. Bergerot, Jacob J. Adashek, Hong Li, Xuesong Yu, Elaina M. Gartner, Anne-Sophie Carret, David C. Smith



Cluster of differentiation 70 (CD70) is frequently expressed in renal cell carcinoma (RCC) and has immunomodulatory properties. An antibody‐drug conjugate targeting CD70, SGN‐CD70A, was developed to treat patients with CD70‐positive RCC.

You might also like
Discover & Discuss Important Research

Keeping up-to-date with research can feel impossible, with papers being published faster than you'll ever be able to read them. That's where Researcher comes in: we're simplifying discovery and making important discussions happen. With over 19,000 sources, including peer-reviewed journals, preprints, blogs, universities, podcasts and Live events across 10 research areas, you'll never miss what's important to you. It's like social media, but better. Oh, and we should mention - it's free.

  • Download from Google Play
  • Download from App Store
  • Download from AppInChina

Researcher displays publicly available abstracts and doesn’t host any full article content. If the content is open access, we will direct clicks from the abstracts to the publisher website and display the PDF copy on our platform. Clicks to view the full text will be directed to the publisher website, where only users with subscriptions or access through their institution are able to view the full article.